Nektar Therapeutics (NKTR)

• Market cap: $926M
• 1 day: 3.14%
• 5 days: 19.58%
• 1 month: 106.27%
• 3 months: 455.71%
• 6 months: 295.77%
• Year to date: 237.59%
• 1 year: 159.63%
• 5 years: -83.57%
• 10 years: -74.08%
• Sector: Healthcare
• Industry: Biotechnology

About: Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Employees: 61

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

135% more capital invested

Capital invested by funds: $84.2M [Q1] → $198M (+$114M) [Q2]

57.47% more ownership

Funds ownership: 4.44% [Q1] → 61.91% (+57.47%) [Q2]

9% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 32

10% less call options, than puts

Call options by funds: $32.1M | Put options by funds: $35.6M

31% less funds holding

Funds holding: 154 [Q1] → 107 (-47) [Q2]

61% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 76

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $85
• Avg. target: $103
• High target: $120

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

B. Riley Securities Mayank Mamtani	$85	Buy Maintained	8 Jul 2025
HC Wainwright & Co. Arthur He	$120	Buy Maintained	24 Jun 2025